Fosaprepitant dimeglumine and Fatigue - a phase IV clinical study of FDA data

Summary:

Fatigue is reported as a side effect among people who take Fosaprepitant dimeglumine (fosaprepitant dimeglumine), especially for people who are female, 40-49 old, have been taking the drug for < 1 month also take Simponi, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Fatigue when taking Fosaprepitant dimeglumine. It is created by eHealthMe based on reports of 1,528 people who have side effects when taking Fosaprepitant dimeglumine from the FDA, and is updated regularly.

What is Fosaprepitant dimeglumine?

Fosaprepitant dimeglumine has active ingredients of fosaprepitant dimeglumine. eHealthMe is studying from 1,528 Fosaprepitant dimeglumine users. Check the latest studies of Fosaprepitant dimeglumine.

What is Fatigue?

Fatigue (feeling of tiredness) is found to be associated with 4,027 drugs and 6,380 conditions by eHealthMe. Check the latest studies of Fatigue.

On Jul, 20, 2026

1,528 people reported to have side effects when taking Fosaprepitant dimeglumine.
Among them, 70 people (4.58%) have Fatigue.

Could Fosaprepitant dimeglumine cause Fatigue?

Among these 70 people:

How long have people been on Fosaprepitant dimeglumine when they have Fatigue? *

What is the gender of people who have Fatigue when taking Fosaprepitant dimeglumine? *

female: 89.39 %
male: 10.61 %

What is the age of people who have Fatigue when taking Fosaprepitant dimeglumine? *

What are other drugs people take besides Fosaprepitant dimeglumine? *

What are other side effects people have besides Fatigue? *

Rashes (redness): 57 people, 81.43%
Gastrointestinal Disorder (functional problems of gastrointestinal tract): 56 people, 80.00%
Dyspnea (difficult or laboured breathing): 55 people, 78.57%
Fever: 53 people, 75.71%
Hepatic Enzyme Increased: 45 people, 64.29%
Joint Swelling: 45 people, 64.29%
Pain: 45 people, 64.29%
Joint Pain: 45 people, 64.29%
Peripheral Swelling: 45 people, 64.29%
Infusion Related Reaction: 44 people, 62.86%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 44 people, 62.86%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 22 people, 31.43%
Tardive Dyskinesia (a disorder that involves involuntary movements): 11 people, 15.71%
Breast Cancer: 11 people, 15.71%
Psoriasis (immune-mediated disease that affects the skin): 9 people, 12.86%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 9 people, 12.86%
Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 7 people, 10.00%
Ankylosing Spondylitis (type of arthritis affecting the spine): 5 people, 7.14%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 5 people, 7.14%
Stress And Anxiety: 4 people, 5.71%

* Approximation only. Some reports may have incomplete information.

Do you take Fosaprepitant dimeglumine and have Fatigue?

- Check whether Fatigue is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Fosaprepitant dimeglumine:

Fosaprepitant dimeglumine (1,528 reports)

Fatigue treatments and more:

Fatigue (967,537 reports)

Browse all side effects of Fosaprepitant dimeglumine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Fatigue:

Fatigue (4,027 drugs)

Browse all the conditions that are associated with Fatigue:

Fatigue (6,380 conditions)

Related publications that referenced our studies

Peel MM, Cooke M, Lewis-Peel HJ, Lea RA, Moyle W, "A randomized controlled trial of coenzyme Q 10 for fatigue in the late-onset sequelae of poliomyelitis", Complementary therapies in medicine, 2015 Dec .
Peel MM, Cooke M, Lewis-Peel HJ, Lea RA, Moyle W, "A randomized controlled trial of coenzyme Q 10 for fatigue in the late-onset sequelae of poliomyelitis", Complementary therapies in medicine, 2015 Dec .

How the study uses the data?

The study uses data from the FDA. It is based on fosaprepitant dimeglumine (the active ingredients of Fosaprepitant dimeglumine) and Fosaprepitant dimeglumine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.